新闻

4月 28, 2022

方达医药收购Experimur 扩展毒理学服务

埃克斯顿，宾夕法尼亚州 January 11th, 2022 – 方达医药美国实验室宣布已完成收购Experimur LLC及其附属公司Experimur Properties LLC的交易。

Experimur, located in Chicago, Illinois, provides full service, GLP-compliant toxicology and related non-clinical development services supporting the pharmaceutical and biotechnology industries. In addition to IND- and NDA-enabling toxicology studies, Experimur’s experience spans extensive developmental, reproductive, and juvenile toxicology, as well as safety pharmacology, transgenic & routine carcinogenicity and general toxicology in all major laboratory species. Additional in-house support services include histology, diagnostic pathology, clinical pathology, and analytical chemistry.

“We are thrilled to welcome the remarkable Experimur team to the Frontage family,” said Glenn Washer, President, North American Operations, and EVP of Global Safety & Toxicology at Frontage Laboratories.  “I believe that the expertise they bring, along with their state-of-the-art 40-room facility and latest equipment, significantly expands Frontage’s already impressive range of services, providing the ability to support our customers’ drug-development programs beyond IND and into Developmental and Reproductive Toxicology (“DART”) and carcinogenicity studies. Frontage recognizes that Experimur’s customer-focus has been key to its success, and we can assure existing customers that we are committed to continuing to offer the same level of service and engagement that they have come to expect.”.

方达医药创始人、董事长兼首席执行官李松博士表示：“Experimur拥有非同寻常的临床前毒理学平台，核心团队拥有超过35年的行业经验。我们非常高兴他们的研究和测试服务能加入到方达现有的业务体系中。我们将继续努力，通过为客户提供最高水平的质量、技术和专业知识，将方达发展成为国际顶尖水平的CRO公司。我相信Experimur的加入是朝着这一方向努力的重要一步。”

Experimur联合创始人兼首席执行官Nabil Hatoum博士表示：“很荣幸通过21年的努力将Experimur打造成今天卓越的CRO公司之一。我们深感加入方达医药大家庭对我们珍视的客户和员工来说都是一次巨大的机遇。Experimur和方达有共同的文化，都专注于客户满意度和致力于最高水平的科学诚信。因此，我们的现有客户不仅将受益于我们对高质量服务的共同承诺，还将受益于方达医药所能提供的更全面的服务。很高兴为方达带来经AAALAC认证和美国农业部注册的54,000平方英尺的先进动物实验设施，我们将致力于尽快将Experimur整合到方达的运营体系中。”